<div id="readability-page-1"><div><ul><li>Generation Bio Co is expected to show a fall in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2025</li><li>The Cambridge Massachusetts-based company is expected to report a 91.3% decrease in revenue to $660 thousand from $7.55 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.</li><li>​LSEG's mean analyst estimate for Generation Bio Co is for a loss of $3.17 per share. </li><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 3 &#34;strong buy&#34; or &#34;buy,&#34; 3 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34; </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for Generation Bio Co is $13.50, about 59.3% above its last closing price of $5.50</li></ul>Previous quarterly performance (using preferred earnings measure in US dollars). ​<div><table><tbody><tr><td>QUARTER ENDING</td><td>STARMINESMARTESTIMATE®</td><td>LSEG IBES ESTIMATE </td><td>ACTUAL</td><td>BEAT, MET, MISSED</td><td>SURPRISE %</td></tr><tr><td>Jun. 30 2025</td><td>-2.73</td><td>-2.85</td><td>-3.12</td><td>Missed</td><td>-9.5</td></tr><tr><td>Mar. 31 2025</td><td>-2.98</td><td>-2.93</td><td>-2.20</td><td>Beat</td><td>25</td></tr><tr><td>Dec. 31 2024</td><td>-2.96</td><td>-3.01</td><td>-3.20</td><td>Missed</td><td>-6.2​</td></tr><tr><td>Sep. 30 2024</td><td>-2.80</td><td>-2.83</td><td>-2.30</td><td>Beat</td><td>18.6</td></tr><tr><td>​​Jun. 30 2024</td><td>-2.89</td><td>-2.78</td><td>-3.10</td><td>Missed</td><td>-11.3</td></tr><tr><td>Mar. 31 2024</td><td>-4.02</td><td>-4.08</td><td>-11.20</td><td>Missed</td><td>-174.4​</td></tr><tr><td>Dec. 31 2023</td><td>-4.39</td><td>-4.49</td><td>-5.30</td><td>Missed</td><td>-18.2</td></tr><tr><td>Sep. 30 2023</td><td>-5.03</td><td>-5.05</td><td>-4.30</td><td>Beat</td><td>14.9</td></tr></tbody></table></div>This summary was machine generated October 31 at 23:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</div></div>

GBIO

Generation Bio Co is projected to report a loss of $3.17 per share and a significant 91.3% drop in quarterly revenue to $660,000 for the period ending September 30, 2025. The average analyst rating remains "buy" with a median 12-month price target of $13.50, reflecting a potential upside of 59.3% from the last closing price of $5.50. Previous earnings reports show mixed results, with several misses and a few beats in the last quarters.

Generation Bio Co expected to post a loss of $3.17 a share - Earnings Preview